Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Plerixafor and GCSF for Stem Cell Mobilization in MM

Leuk Lymphoma; ePub 2016 Oct 13; Ogunniyi, et al

Publish date:: October 19, 2016

Plerixafor combined with granulocyte-colony stimulating factor (GCSF) was effective for stem cell collection in people with multiple myeloma in a study involving 138 individuals.

Investigators looked at the ability of plerixafor + GCSF to collect enough stem cells to safely allow 2 transplants. They also analyzed risk factors involved in such mobilization. Among the results:

The stem cell collection success rate was nearly 93%.
Lenalidomide alone, white blood cell count <4 × 10³/mcL prior to mobilization, and non-African American race were identified as risk factors for low efficiency.

Citation:

Ogunniyi A, Rodriguez M, Devlin S, et al. Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: Efficacy and analysis of risk factors associated with poor stem cell collection efficiency. [Published online ahead of print October 13, 2016]. Leuk Lymphoma. doi:10.1080/10428194.2016.1239261.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Cellular Therapy

CAR T-cell therapy may worsen mental health in some patients,

New Toxicity Subscale Measures QOL in Cancer Patients on Checkpoint Inhibitors,

CAR T cells produce complete responses in T-cell malignancies,

CAR T-cell therapy advances in CLL,

Inhibitor appears to strengthen anti-BCMA CAR T cells in myeloma patients,